Consorzio Interuniversitario Nazionale per la Bio-Oncologia www.cinbo.org
DIRECTOR Clara Natoli SCIENTIFIC SECRETARIAT
Consiglia Carella Michele De Tursi Antonino Grassadonia
Nicola Tinari
SCIENTIFIC ADVISORY BOARD Vincenzo Adamo Massimo Aglietta Roberto Bianco Giovanni Brandi Marco Carini Leonardo Della Salda
Corrado Ficorella Francesco Grignani
Lorenzo Lo Muzio Patrizia Querzoli
Antonio Russo Marina Scarpelli
Silverio Tomao Giuseppe Tonini ORGANIZING SECRETARIAT
Giovanna Di Credico OFFICES
Consorzio Interuniversitario Nazionale per la Bio-Oncologia (CINBO) c/o Sezione di Oncologia Medica Università G. D’Annunzio - Via dei Vestini, 31
66100 Chieti - Italy Phone: +39 0871 3556732
Fax +39 0871 3556707 [email protected] PROVIDER ECM ID. 50
Strategie S.r.L. - Via Piave 110/7 - Pescara Phone: 085 74143 - Fax: 085 378220
[email protected] www.strategieonweb.it
BREAST CANCER NEWS
September 28, 2018
SALA CONVEGNI
Centro Scienze dell’Invecchiamento e Medicina Traslazionale (Ce.S.I.-Me.T.) Via Luigi Polacchi 11/13 - Chieti
Directors Clara Natoli
Corrado Ficorella
CINBO
Consorzio Interuniversitario Nazionale per la Bio-Oncologia
Evento n. ECM 50-234621 Per Medici Chirurghi specialisti in:
ALLERGOLOGIA ED IMMUNOLOGIA CLINICA; EMATOLOGIA;
ENDOCRINOLOGIA; GENETICA MEDICA; ONCOLOGIA;
RADIOTERAPIA; CHIRURGIA GENERALE; CHIRURGIA PLASTICA E RICOSTRUTTIVA; GINECOLOGIA E OSTETRICIA; ANATOMIA PATOLOGICA; FARMACOLOGIA E TOSSICOLOGIA CLINICA;
MEDICINA NUCLEARE; RADIODIAGNOSTICA;
Per Biologi;
Per Farmacisti (Farmacia Ospedaliera);
Crediti ECM: 6
si ringrazia per il contributo incondizionato:
La partecipazione è gratuita.
Le iscrizioni si accettano on line sul sito del Provider www.strategieonweb.it - pagina ECM 2018
Con il patrocino di:
Stampa Demagraf - Pescara
Educational School of Oncology - CINBO (ESO-CINBO)
Registration & Welcome coffee Introduction
Clara Natoli & Corrado Ficorella
Session I
Moderators: Carlo Garufi , Corrado Ficorella
Is it better adjuvant or neoadjuvant chemotherapy in high risk early breast cancer?
Giuliana D’Auria, Rome Discussion
Adjuvant bone targeted therapies in early breast cancer
Olga Venditti, L’Aquila Discussion
Prognostic impact of Body Mass Index in metastatic breast cancer
Maddalena Barba, Rome Discussion
Coffee break
Session II
Moderators: Nicola D’Ostilio, Amedeo Pancotti
Local therapy for the primary breast cancer in women with advanced stage disease
Alberto Bafi le, L’Aquila Discussion
Beyond the third line: how much is enough in metastatic breast cancer treatment?
Marinella Zilli, Chieti Discussion
Lecture: Cost-effectiveness and sustainability of new anti-breast cancer drugs
Giorgio Mustacchi, Trieste Light lunch
Program
Alberto Bafi le albertobafi [email protected] L’Aquila
Maddalena Barba
[email protected] Rome
Katia Cannita [email protected] L’Aquila
Licia Caprara
[email protected] Chieti
Ettore Cianchetti [email protected] Ortona (CH) Giuliana D’Auria
[email protected] Rome
Nicola D’Ostilio
[email protected] Lanciano (CH)
Anna Di Profi o
annadiprofi [email protected] Chieti
Corrado Ficorella corrado.fi [email protected] L’Aquila
Samantha Forciniti [email protected] Lanciano (CH) Carlo Garufi
carlo.garufi @ausl.pe.it Pescara
Valentina Manso
[email protected] Chieti
Antonio Marchetti [email protected] Chieti
Vera Martinella
[email protected] Milan
Alfonso Mascitelli
[email protected] Pescara
Mariella Mauri
[email protected] Rome
Raffaella Muraro [email protected] Chieti
Giorgio Mustacchi [email protected] Trieste
Clara Natoli [email protected] Chieti
Amedeo Pancotti [email protected] Teramo
Laura Pizzuti [email protected] Rome
Maria Teresa Scognamiglio [email protected] Ortona (CH)
Olga Venditti [email protected] L’Aquila
Patrizia Vici
[email protected] Rome
Marinella Zilli [email protected] Chieti
9.15 Registration & Welcome coffee 9.45 Introduction
10.00 Is it better adjuvant or neoadjuvant chemotherapy in high risk
10.50 Prognostic impact of Body Mass Index 11.00
11.30 Local therapy for the primary breast cancer in women 10.30 Adjuvant bone targeted therapies
Faculty
10.20
11.10 10.40
11.40
11. 50 Beyond the third line: how much is enough in metastatic
12.10
12.20 Lecture: Cost-effectiveness and sustainability of
13.00
Session III
Moderators:Patrizia Vici, Clara Natoli
Sequences of treatments in HR+/HER2- metastatic breast cancer
Katia Cannita, L’Aquila Discussion
Sequences of treatments in HER2+ metastatic breast cancer Samantha Forciniti, Lanciano (Ch)
Discussion
Sequences of treatments in triple negative metastatic breast cancer
Laura Pizzuti, Rome Discussion
Precision Medicine for Breast Cancer: a near future?
Antonio Marchetti, Chieti Discussion
Session IV
Moderators:Alfonso Mascitelli, Licia Caprara, Raffaella Muraro Round Table - How much work behind EUSOMA certifi cate?
Ettore Cianchetti, Chieti Valentina Manso, Chieti Mariella Mauri, Rome
From “Fake News” to “Real News”
Vera Martinella, Milan
Financial toxicity of breast cancer diagnosis Maria Teresa Scognamiglio, Ortona (CH)
The supportive role of breast cancer patients associations Anna Di Profi o, GAIA
Discussion
Take-home messages and conclusions
14.00 Sequences of treatments in HR+/HER2- metastatic
14.20
14.30 Sequences of treatments in HER2+ metastatic breast cancer 14.50
15.20
15.30 Precision Medicine for Breast Cancer: a near future?
15.00 Sequences of treatments in triple negative
15.50
16.00 Round Table - How much work behind EUSOMA certifi cate?
16.45 From “Fake News” to “Real News”
17.00 Financial toxicity of breast cancer diagnosis
17.30 The supportive role of breast cancer patients associations 17.45
18.15 Take-home messages and conclusions
